DAA治疗与晚期/失代偿期肝硬化长期肝功能:HCV-TARGET真实世界经验
基于HCV-TARGET队列中642例晚期/失代偿期肝硬化(MELD≥10)患者,含NS5A的DAA治疗后90.5%获得SVR12;短期24%患者MELD下降≥3分,但长期随访(中位4年)MELD、胆红素和白蛋白仅边际变化,29%患者MELD下降≥3分。
要点
- 含NS5A的DAA方案在晚期/失代偿期肝硬化中SVR12达90.5%。
- 短期24%患者MELD下降≥3分,但长期仅边际改善。
- 长期随访中29%患者MELD下降≥3分,25%最终MELD<10。
核心结论
- 晚期/失代偿期HCV肝硬化患者经DAA获得SVR12后,长期MELD、总胆红素和白蛋白仅边际改善。
研究设计与样本
- HCV-TARGET真实世界队列研究,纳入642例晚期/失代偿期肝硬化(MELD≥10)患者,2018年9月前启动含NS5A的DAA治疗。
主要发现
- 642例患者平均年龄60岁,68%为男性,基线MELD中位数12(范围10-39),64%有既往失代偿史。
- 可评估病毒学结局的患者中90.5%获得SVR12。
- 长期随访(治疗后中位4年)MELD平均变化-0.30分,总胆红素+0.23 mg/dl,白蛋白+0.36 g/dl。
临床怎么用
- 晚期/失代偿期HCV肝硬化患者即使获得SVR12,仍需密切监测肝功能及失代偿风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Direct-acting antiviral (DAA) therapy is used in patients with HCV-related decompensated cirrhosis with the expectation of improving hepatic function. However, little is known about the long-term hepatic benefit of successful antiviral treatment. METHODS: Patients with advanced/decompensated cirrhosis (model for end-stage liver disease [MELD] ≥10), in whom NS5A-containing DAA therapy was initiated prior to September 2018, were included (from the HCV-TARGET cohort). Treatment outcomes and the impact of treatment on short-term and long-term hepatic function were examined. RESULTS: A total of 642 patients were analyzed. The mean age was 60 years, 68% were male. The median baseline MELD was 12 (range 10-39) and 64% had prior decompensation. Among patients with available virologic outcomes, 90.5% achieved a sustained virologic response at 12 weeks (SVR12). Eighty (24%) patients achieved a clinically significant decrease in MELD by ≥3 points during short-term follow-up (9-26 weeks after the end of treatment). However, in long-term follow-up (median of 4 years after treatment), mean changes in MELD (-0.30 points), total bilirubin (+0.23 mg/dl) and albumin (+0.36 g/dl) were marginal. Fifty-one patients died and 22 underwent liver transplant. In long-term follow-up, a clinically meaningful decrease in MELD of ≥3 occurred in 29% and a final MELD score of <10 was achieved in 25%. CONCLUSION: In a large real-world experience of patients with advanced/decompensated HCV-related cirrhosis treated with DAAs, there were only marginal improvements in MELD, total bilirubin, or albumin at long-term follow-up (after achieving SVR12). These patients may remain at high risk of decompensation and must continue to be closely monitored. CLINICALTRIALS.GOV: NCT01474811. LAY SUMMARY: Hepatitis C virus infection can now be cured with medications, even in patients who have advanced scarring of the liver (cirrhosis). In this study, we evaluated whether liver function improves or deteriorates in the long-term, following successful treatment of hepatitis C in patients with cirrhosis. We found that overall liver function was relatively stable with only 29% of patients achieving a clinically meaningful improvement in liver function, and we therefore believe that these patients require ongoing monitoring.
引用
- Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020. PMID: 32243960. doi:10.1016/j.jhep.2020.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。